This database contains 1433 studies, archived under the term: ""
Click here to filter this large number of results.
Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial
Barnes, Deborah E.,
Yaffe, Kristine,
Belfor, Nataliya,
Jagust, William J.,
DeCarli, Charles,
Reed, Bruce R.,
Kramer, Joel H.
We performed a pilot randomized, controlled trial of intensive, computer-based cognitive training in 47 subjects with mild cognitive impairment. The intervention group performed exercises specifically designed to improve auditory processing speed and accuracy for 100 min/d, 5 d/wk for 6 weeks; the control group performed more passive computer activities (reading, listening, visuospatial game) for similar […]
Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer’s disease: a 3-year follow-up longitudinal study
Angelucci, Francesco,
Bernardini, Sergio,
Gravina, Paolo,
Bellincampi, Lorenza,
Trequattrini, Alberto,
Di Iulio, Fulvia,
Vanni, Diego,
Federici, Giorgio,
Caltagirone, Carlo,
Bossù, Paola,
Spalletta, Gianfranco
Although the etiology of psychotic symptoms (hallucinations and delusions) in Alzheimer’s disease is still not known, alterations in serotonergic neurotransmission have been proposed. In a 3-year follow-up study, we evaluated the association of serotonin (5-HT) receptor 5-HT2a 102T/C polymorphism (allelic variants CC, CT and TT) with psychotic symptom severity and response to treatment with atypical […]
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin
Alvarez, X. Anton,
Sampedro, Carolina,
Cacabelos, Ramon,
Linares, Carlos,
Aleixandre, Manuel,
García-Fantini, Manuel,
Moessler, Herbert
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]
Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer’s disease
This study investigated the relationship between premorbid and current cognitive function with respect to the clinical features of patients with various types of neurodegeneration in the form of Alzheimer’s disease (AD), mild cognitive impairment (MCI), and subjective cognitive impairment (SCI), as compared with a healthy control group (C). Clinical features (MMSE, cognitive and depressive symptoms), […]
Incidence and prediction of falls in dementia: a prospective study in older people
Background: Falls are a major cause of morbidity and mortality in dementia, but there have been no prospective studies of risk factors for falling specific to this patient population, and no successful falls intervention/prevention trials. This prospective study aimed to identify modifiable risk factors for falling in older people with mild to moderate dementia.; Methods […]
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Santoro, Aurelia,
Siviero, Paola,
Minicuci, Nadia,
Bellavista, Elena,
Mishto, Michele,
Olivieri, Fabiola,
Marchegiani, Francesca,
Chiamenti, Andrea Maria,
Benussi, Luisa,
Ghidoni, Roberta,
Nacmias, Benedetta,
Bagnoli, Silvia,
Ginestroni, Andrea,
Scarpino, Osvaldo,
Feraco, Emidio,
Gianni, Walter,
Cruciani, Guido,
Paganelli, Roberto,
Di Iorio, Angelo,
Scognamiglio, Mario,
Grimaldi, Luigi Maria Edoardo,
Gabelli, Carlo,
Sorbi, Sandro,
Binetti, Giuliano,
Crepaldi, Gaetano,
Franceschi, Claudio
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]
Plasma concentration of donepezil to the therapeutic response of Alzheimer’s disease in Taiwanese
Yang, Yuan-Han,
Wu, Shey-Lin,
Chou, Mei-Chuan,
Lai, Chiou-Lian,
Chen, Su-Hwei,
Liu, Ching-Kuan
Donepezil has been approved for the treatment for mild-to-moderate Alzheimer’s disease (AD), but the therapeutic response rate varies from 20 to 60%. A higher oral dosage was suggested to have a better therapeutic response in reported results, but the plasma concentration of donepezil was not examined with respect to the therapeutic outcomes in those studies. […]
Non-pharmacological management of behavioural symptoms of dementia
This article describes a 6-month pilot project in which a community mental health team provided a dementia inreach service into 4 care homes in Birmingham, UK. The project included analysis of the impact of the service at the end of the project as well as a literature review of dementia care in care homes, and […]
Effect of music on pain for home-dwelling persons with dementia
The purpose of this study was to investigate the effect of music on pain for home-dwelling persons with dementia. A quasiexperimental design was used. Fifteen subjects listened to their preferred music for 30 minutes before peak agitation time, for 2 days per week, followed by no music for 2 weeks. The process was repeated once. […]
The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer’s disease risk: a prospective cohort study
Keller, Lina,
Xu, Weili,
Wang, Hui-Xin,
Winblad, Bengt,
Fratiglioni, Laura,
Graff, Caroline
The FTO gene has been shown to have a small but robust effect on body mass index (BMI) and to increase the risk for diabetes. Both high BMI and diabetes are vascular risk factors that might play a role in the development of Alzheimer’s disease (AD) and dementia. Thus, our aim was to explore the […]